YBGJ (Yubo International Biotech) Beginning Cash Position: $0.01 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Yubo International Biotech Beginning Cash Position?

Yubo International Biotech YBGJ Beginning Cash Position is $0.01 Mil as of Jun. 2026. The stock has 2 warning signs investors should review.

Yubo International Biotech's Beginning Cash Position for the quarter that ended in Jun. 2026 was $0.01 Mil.

Yubo International Biotech's quarterly Beginning Cash Position declined from Dec. 2025 ($0.01 Mil) to Mar. 2026 ($0.01 Mil) but then increased from Mar. 2026 ($0.01 Mil) to Jun. 2026 ($0.01 Mil).

Yubo International Biotech's annual Beginning Cash Position declined from Dec. 2023 ($0.02 Mil) to Dec. 2024 ($0.01 Mil) and declined from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($0.01 Mil).

Yubo International Biotech Beginning Cash Position Related Terms

Yubo International Biotech Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Yubo International Biotech's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yubo International Biotech Beginning Cash Position Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 1.38 0.03 0.02 0.01 0.01

Yubo International Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Yubo International Biotech Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.01 Mil mean?
Yubo International Biotech (YBGJ) has a Beginning Cash Position of $0.01 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Yubo International Biotech and its competitors.
Is Yubo International Biotech's Beginning Cash Position too high?
Yubo International Biotech's current Beginning Cash Position is $0.01 Mil.
How does Yubo International Biotech's Beginning Cash Position compare to ECIA and NXGL?
Yubo International Biotech's Beginning Cash Position of $0.01 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Yubo International Biotech and its competitors. Yubo International Biotech's current Beginning Cash Position is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yubo International Biotech stock overvalued right now?
Yubo International Biotech (YBGJ) has a current Beginning Cash Position of $0.01 Mil. The current Beginning Cash Position is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Yubo International Biotech (YBGJ), the current Beginning Cash Position is $0.01 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yubo International Biotech Business Description

Address No. 10 Chaoyang Park South Road, Room 1102, 11th Floor, Building 2, Chaoyang District, Beijing, CHN, 100026
Yubo International Biotech Ltd is a technology company focused on the research, development, and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.